Clinical Practice Session
Novel Anticancer Therapies and Hypertension: The Role of the Nephrologist
November 03, 2022 | 10:30 AM - 12:30 PM
Location: W311, Orange County Convention Center, West Building
Session Description
Several international guidelines and an American Heart Association statement are expected in the next year about hypertension in patients with cancer. Nephrologists are at the forefront of helping to diagnose, monitor, and manage these patients. There are important distinctions in the mechanisms of cancer therapy that drive higher risk of hypertension in patients undergoing treatment. This session provides an overview of the nephrologist's role with these patients, who require different approaches to monitoring and management than the general population.
Learning Objective(s)
- Describe the prevalence of hypertension among patients undergoing cancer therapy and its distinctive impact on target organs
- Identify the mechanisms of hypertension induced by anticancer therapies
- Discuss the unique aspects of diagnosis, monitoring, and management of hypertension in patients with cancer
Learning Pathway(s)
- Hypertension and Cardiorenal Disorders
- Onconephrology
Moderators
- Kenar D. Jhaveri, MD, FASN
- Sheron Latcha, MD, FASN
Presentations
- New-Onset Hypertension in Patients with Cancer Secondary to Cancer Therapies
10:30 AM - 11:00 AM
Gavin Oudit, MD, PhD
- Mechanisms of Hypertension due to Vascular Endothelial Growth Factor (VEGF) Inhibitors
11:00 AM - 11:30 AM
Vesna D. Garovic, MD, PhD, FASN
- Hypertension due to Non-VEGF-Pathway Anticancer Therapies
11:30 AM - 12:00 PM
Sandra Herrmann, MD
- Distinct Approaches to Diagnosing, Monitoring, and Managing Hypertension in Patients with Cancer
12:00 PM - 12:30 PM
Agnes S. Kim, MD, PhD
